The flagship company of the Torrent Group, Torrent Pharmaceuticals Limited is a major player in the Indian pharmaceuticals sector with the vision of becoming a global entity. Torrent Pharma enjoys dominance in the niche therapeutic areas like, cardiovascular and central nervous system, gastro-intestinal, pain management and oral anti-diabetic segments.Torrent Pharma owes its success in the domestic market to its thrust on frontline research, strategic marketing and world-class manufacturing. It is among the largest spenders on R&D and has set up one of the most advanced research centers in the country at an investment of Rs. 200 crores so far. It has discovered and patented the AGE (Advanced Glycosylation End Product) Breaker Compound which has potential to treat heart diseases and diabetes related vascular complications. Its manufacturing facilities have received quality certifications from various international regulatory authorities.It is this success that Torrent Pharma attempts to replicate in the international market now. It has already established fully-owned subsidiaries in Australia , Brazil , Germany , Japan , Mexico , Philippines Russia and USA and has over 1000 product registrations in more than 50 countries worldwide
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes us one of the most rewarding employers in our field.
Aurigene is a Bangalore based world-class drug discovery company with integrated capabilities for discovery and development of novel small molecule drugs.Aurigene provides Drug Discovery Services for Lead Generation/ Lead Optimization. The Business Model involves collaborative Drug Discovery with partners, on a risk- and reward-sharing basis. Typical Aurigene projects involve starting with a partner’s target protein and delivering an Optimized Lead, ready to go into clinical development.Aurigene employs both Structure Guided Drug Design (SGDD) and conventional Screening technologies for Drug Discovery. SGDD involves structural screening, computational chemistry aided ligand design, mining and screening of novel chemical entities, thus providing direction for Lead Discovery and Medicinal Chemistry. Early animal work involving ADME and Toxicity improves the probability of success. The approach helps in identifying the challenges at a very early stage and helps in setting a road map for the next steps in the process, thus shortening the overall project timelines and thereby mitigating risks.Aurigene is also identifying and building a portfolio of product opportunities focused on metabolic disorders, cardiovascular diseases, oncology and inflammatory diseases. Programs are chosen for significant unmet needs, and start with validated disease targets having well-defined roadmaps for clinical development. These are projects specifically designed for partnering with Pharma and Discovery Biotech companies.Target focus includes Kinases, Proteases, Nuclear Hormone Receptors and G-Protein Coupled Receptors.Using the strength of its technology and approach, Aurigene is able to provide novel solutions; its capabilities include significant speed and cost-effective innovation, coupled with the ability to rapidly scale-up scientific capabilities.Aurigene is founded by Dr Reddy’s Laboratories Limited (DRL). DRL is listed both on the New York Stock Exchange (NYSE) and Bombay Stock Exchange (BSE) with significant operations in USA and Europe.